Breaking News Instant updates and real-time market news.

MGNX

MacroGenics

$13.89

0.17 (1.24%)

, QURE

uniQure

$56.06

0.64 (1.15%)

04:55
09/05/19
09/05
04:55
09/05/19
04:55

Citigroup to hold a conference

14th Annual Biotech Conference will be held in Boston on September 4-5.

MGNX

MacroGenics

$13.89

0.17 (1.24%)

QURE

uniQure

$56.06

0.64 (1.15%)

RGNX

Regenxbio

$32.97

-0.34 (-1.02%)

TPTX

Turning Point Therapeutics

$48.27

-2.93 (-5.72%)

ZYME

Zymeworks

$27.10

1.1 (4.23%)

MLND

Millendo Therapeutics

$4.90

0.13 (2.73%)

BOLD

Audentes Therapeutics

$29.60

-0.35 (-1.17%)

CALA

Calithera Biosciences

$3.78

-0.135 (-3.45%)

DERM

Dermira

$7.63

-0.19 (-2.43%)

EDIT

Editas Medicine

$23.17

-0.71 (-2.97%)

PIRS

Pieris Pharmaceuticals

$4.99

0.15 (3.10%)

  • 05

    Sep

  • 05

    Sep

  • 05

    Sep

  • 09

    Sep

  • 09

    Sep

  • 11

    Sep

  • 24

    Sep

  • 27

    Sep

  • 06

    Sep

  • 06

    Sep

MGNX MacroGenics
$13.89

0.17 (1.24%)

07/18/19
HCWC
07/18/19
NO CHANGE
Target $39
HCWC
Buy
H.C. Wainwright sees 'nothing sinister' with MacroGenics regaining drug rights
H.C. Wainwright analyst Debjit Chattopadhyay sees nothing "inherently sinister" with flotetuzumab after MacroGenics regained the full rights to the drug. After speaking with management, the analyst says that ex-partner Servier was not been particularly engaged during the development process and that to date, MacroGenics has been funding both the U.S. and European studies. Further, flotetuzumab's emerging clinical profile remains consistent with what was presented at ASH 2018, and an updated presentation on the fully enrolled dose expansion cohort is expected at ASH 2019, Chattopadhyay tells investors in a research note. He keeps a Buy rating on MacroGenics shares with a $39 price target.
06/05/19
STFL
06/05/19
NO CHANGE
Target $29
STFL
Buy
MacroGenics price target lowered to $29 from $36 at Stifel
Stephen analyst Kevin Willey lowered his price target for MacroGenics to $29 from $36, saying he expects maturing overall survival data from Sophia to command "meaningful" regulatory and commercial importance given what is likely to remain perceived to be a progression free survival benefit of uncertain clinical relevance. Willey tells investors in a research note that he is now less optimistic directionally-supportive OS data will manifest over time in the intent-to-treat patient population and has "minimal" confidence the early numerical OS separation favoring margetuximab in CD16A-158F patients will prove durable. He maintains a Buy rating.
06/04/19
STFL
06/04/19
NO CHANGE
STFL
Stifel 'gut reaction' to margetuximab data aligns with 19% selloff
Stifel analyst Stephen Willey says his "gut reaction" to today's more-detailed Sophia data appears to align with how the stock is trading post this morning's presentation. Shares of MacroGenics are down 19%, or $3.55, to $15.17 in midday trading. The analyst found the overall survival data of margetuximab the most disappointing. He had hoped the large absolute median OS benefit in low-affinity CD16A-158 patients favoring margetuximab would offset some of the concern around the clinical relevance of the progression free survival benefit. Unfortunately, however, this benefit appears to be less compelling when viewed in the context of the full Kaplan-Meier curve, Willey tells investors in a research note titled "First Take on SOPHIA Data Presentation - Don't Expect OS to Pick Up the PFS Slack." The analyst continues to believe the Sophia data represents an approvable data set, but he admits the addressable market opportunity is "likely now amplified following today's presentation." The continued perception of margetuximab as an overhang could serve to keep near-term enthusiasm in MacroGenics shares "muted," says Willey. He keeps a Buy rating on the shares.
05/16/19
FBCO
05/16/19
NO CHANGE
Target $29
FBCO
Outperform
MacroGenics SOPHIA abstract leaves more questions than answers, says Credit Suisse
Commenting on MacroGenics' Phase 3 SOPHIA trial, Credit Suisse analyst Michael Morabito says that physician experts with whom he has been consulting were hoping for a benefit of at least 2 months compared to Herceptin, which they would consider practice changing in this third-line setting of patients who progressed on Herceptin/Perjeta/Kadcyla. With the net benefit for margetuximab coming in at only 0.9 months, the analyst would expect the shares could see increased pressure on this data. He reiterates an Outperform rating and $29 price target on the shares.
QURE uniQure
$56.06

0.64 (1.15%)

07/29/19
GUGG
07/29/19
DOWNGRADE
GUGG
Neutral
uniQure downgraded to Neutral from Buy at Guggenheim
07/08/19
CANT
07/08/19
NO CHANGE
Target $94
CANT
Overweight
uniQure price target raised to $94 from $81 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for uniQure to $94 from $81 after the company over the weekend presented nine-month data from the Phase 2b trial of AMT-061 in hemophilia B. The analyst remains optimistic that uniQure has the "best-in-class" hemophilia B gene therapy product. Further, he thinks new interest could emerge from the company's pipeline beyond hemophilia B this year. Piros reiterates an Overweight rating on uniQure shares.
09/03/19
HCWC
09/03/19
NO CHANGE
Target $73
HCWC
Buy
uniQure has significant first mover advantage in Hem B, says H.C. Wainwright
After uniQure (QURE) announced it has completed enrollment in the HOPE-B registration study, H.C. Wainwright analyst Debjit Chattopadhyay said he now anticipates a likely commercial launch during the fourth quarter of 2021, which is ahead of his prior expectation for launch in the second half of 2022. He sees AMT-061 with a 12+ month lead to be the first commercially viable gene therapy for Hemophilia B and contends the "first mover advantage is likely to be significant," especially if the product's safety profile, established manufacturing, clinical outcomes and clinical lead are compelling enough for Pfizer (PFE) to have second thoughts for its "potentially inferior me-too program" for SPK-9001. Chattopadhyay keeps a Buy rating and $73 price target on uniQure shares.
07/30/19
GUGG
07/30/19
DOWNGRADE
GUGG
Neutral
Guggenheim downgrades uniQure with shares up 127% year-to-date
Guggenheim analyst Whitney Ijem downgraded uniQure to Neutral from Buy without a price target. The analyst continues to see value in the company's lead program AMT-061 for hemophilia B, earlier stage pipeline, and wholly owned manufacturing capability. However, with the shares up 127% year-to-date and a "relatively catalyst light" second half of 2019, Ijem prefers to step the sidelines.
RGNX Regenxbio
$32.97

-0.34 (-1.02%)

08/20/19
LEER
08/20/19
UPGRADE
LEER
Market Perform
Regenxbio upgraded to Market Perform from Underperform at SVB Leerink
SVB Leerink analyst Mani Foroohar upgraded Regenxbio to Market Perform from Underperform with a $37 price target.
06/13/19
RAJA
06/13/19
INITIATION
Target $60
RAJA
Outperform
Regenxbio resumed with an Outperform at Raymond James
Raymond James analyst Dane Leone resumed Regenxbio with an Outperform rating and a price target of $60.
08/20/19
LEER
08/20/19
UPGRADE
Target $37
LEER
Market Perform
Regenxbio upgraded to Market Perform on valuation at SVB Leerink
As previously reported, SVB Leerink analyst Mani Foroohar upgraded Regenxbio (RGNX) to Market Perform from Underperform, with a $37 price target, despite long-term headwinds. The analyst believes the current valuation balances the challenges of the company's partnership strategy and early-stage gene therapy pipeline with attractive anticipated royalty streams from Zolgensma and the competitive risk from Adverum Biotechnologies (ADVM) in wet AMD well-appreciated by investors. Nonetheless, Foroohar continues to have reservations about the long-term outlook for the company - intellectual property from the NAV platform has a finite lifetime, which self-limits royalty streams and exposes the company to litigation risk. As core patents approach expiry, the rate of new partnerships should continue to decrease, he adds.
06/05/19
CHDN
06/05/19
NO CHANGE
Target $145
CHDN
Buy
Regenxbio price target raised to $145 from $127 at Chardan
Chardan analyst Gbola Amusa raised his price target for Regenxbio to $145 from $127 ahead of profitability in 2020 on Zolgensma. Amusa notes that analysts are "unwilling" to model Regenxbio's portfolio of 5 internal and 25 external programs, and reiterates a Buy rating on the shares.
TPTX Turning Point Therapeutics
$48.27

-2.93 (-5.72%)

05/13/19
05/13/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Pinterest (PINS) initiated with an Outperform at Baird, a Buy at Citi, a Sector Perform at RBC Capital, a Hold at Deutsche Bank, a Neutral at Credit Suisse, UBS, BofA/Merrill, Goldman Sachs, and JPMorgan, and an Equal Weight at Barclays. 2. Zoom Video (ZM) initiated with an Overweight at JPMorgan and Piper Jaffray, a Buy at BofA/Merrill, a Market Perform at Wells Fargo and JMP Securities, a Sector Perform at RBC Capital, a Sector Weight at KeyBanc, an Equal Weight at Morgan Stanley, a Hold at Stifel, and a Neutral at Credit Suisse and Goldman Sachs. 3. Turning Point Therapeutics (TPTX) initiated with an Outperform at Wells Fargo and a Buy at Canaccord and Goldman Sachs. 4. Brigham Minerals (MNRL) initiated with an Overweight at Piper Jaffray and Barclays, an Outperform at Wells Fargo, RBC Capital, and Credit Suisse, and a Buy at Goldman Sachs and UBS. 5. Brainsway (BWAY) initiated with an Outperform at Raymond James and Oppenheimer, a Buy at Ladenburg, and Overweight at Cantor Fitzgerald. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/24/19
GUGG
07/24/19
INITIATION
Target $58
GUGG
Buy
Turning Point Therapeutics initiated with a Buy at Guggenheim
Guggenheim analyst Michael Schmidt initiated coverage of Turning Point Therapeutics with a Buy rating and $58 price target, stating that the market for selective tyrosine kinase inhibitors, or TKIs, targeting rare driver mutations in oncology represents a large and growing opportunity. The company's lead product candidate, repotrectinib, has demonstrated early but potent activity in certain non-small cell lung cancer patients positive and may be a best-in-class inhibitor for some solid tumor patients, Schmidt said.
09/04/19
WELS
09/04/19
NO CHANGE
Target $62
WELS
Outperform
Turning Point Therapeutics price target raised to $62 from $53 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Turning Point Therapeutics to $62 from $53 following updated interim phase 1/2 TRIDENT-1 data for repotrectinib in ROS1+ NSCLC and TRK+ solid tumors. The analyst reiterates an Outperform rating on the shares.
07/24/19
07/24/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sharps Compliance (SMED) initiated with a Buy at Roth Capital. 2. MobileIron (MOBL) initiated with a Buy at Craig-Hallum. 3. Berry Global (BERY) resumed with an Outperform at Wells Fargo. 4. Turning Point Therapeutics (TPTX) initiated with a Buy at Guggenheim. 5. Universal Display (OLED) initiated with a Hold at Berenberg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ZYME Zymeworks
$27.10

1.1 (4.23%)

07/18/19
DBAB
07/18/19
INITIATION
Target $34
DBAB
Buy
Zymeworks initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Konstantinos Aprilakis started Zymeworks with a Buy rating and $34 price target. The analyst initiated coverage on eight smid-cap Biotechnology stocks in the oncology space.
08/30/19
08/30/19
INITIATION

Fly Intel: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Orchard Therapeutics (ORTX) initiated with an Outperform at Oppenheimer. 2. Zymeworks (ZYME) initiated with a Buy at Stifel. 3. Modine Manufacturing (MOD) initiated with a Neutral at DA Davidson. 4. AMTD International (HKIB) initiated with a Buy at Loop Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, Reference Link
08/30/19
STFL
08/30/19
INITIATION
Target $45
STFL
Buy
Zymeworks initiated with a Buy at Stifel
Stifel analyst Stephen Willey started Zymeworks with a Buy rating and $45 price target. After successfully leveraging its core antibody engineering platform technologies to generate multiple strategic collaborations and develop two mostly wholly-owned clinical candidates, Zymeworks is now approaching a number of clinical inflection points and appears "poised for meaningful value creation," Willey tells investors in a research note. He believes W25/ZW49 are unique assets within an "increasingly-crowded" development landscape of next-generation HER2- targeting agents.
08/27/19
SBSH
08/27/19
NO CHANGE
Target $49
SBSH
Buy
Zymeworks price target raised to $49 from $22 at Citi
Citi analyst Yigal Nochomovitz raised his price target for Zymeworks to $49 from $22 and keeps a Buy rating on the shares. Despite the shares rallying 70% year-to-date, investors need to pay closer attention to Zymeworks' HER2 antibody-drug-conjugate ZW49, Nochomovitz tells investors in a research note. The analyst believes Investors "need to identify promising assets ever earlier in the valuation cycle to consistently get an edge with a large enough position to matter." He believes believe ZW49 could be transformative for Zymeworks and that the company should be worth $2B, or his $49 per share price target.
MLND Millendo Therapeutics
$4.90

0.13 (2.73%)

07/19/19
WEDB
07/19/19
INITIATION
Target $24
WEDB
Outperform
Millendo Therapeutics initiated with an Outperform at Wedbush
Wedbush analyst Laura Chico initiated Millendo Therapeutics with an Outperform rating and $24 price target. In a research note to investors, Chico notes that the company's lead asset livoletide is in a registrational study for the treatment of Prader-Willi syndrome, which affects roughly 10,000 patients in the U.S. Data from the ZEPHYR study is set to arrive in the first half of 2020, and, with additional data coming for Millendo's nevanimibe, expects Millendo to approach an important value-creating period. While shares have come under recent pressure since June, Chico says she sees favorable risk/reward with cash offering limited downside protection, and livoletide success helping shares work towards the $24 price target.
07/18/19
WEDB
07/18/19
INITIATION
Target $24
WEDB
Outperform
Millendo Therapeutics initiated with an Outperform at Wedbush
Wedbush initiated Millendo Therapeutics with an Outperform rating and $24 price target.
03/13/19
JEFF
03/13/19
INITIATION
Target $22
JEFF
Buy
Millendo Therapeutics initiated with a Buy at Jefferies
Jefferies analyst David Hoang started Millendo Therapeutics with a Buy rating and $22 price target. The company is developing livoletide for Prader Willi syndrome and nevanimibe for congenital adrenal hyperplasia, Hoang tells investors in a research note. He believes the Street is giving little credit to these orphan diseases despite positive Phase IIa data and "sizable" revenue opportunities. The analyst says Millendo's risk/reward looks skewed to the upside.
07/15/19
OPCO
07/15/19
INITIATION
Target $26
OPCO
Outperform
Millendo Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Jay Olson initiated Millendo Therapeutics with an Outperform rating and $26 price target, citing his view on the company's drugs in development for Prader Willi Syndrome, Congenital Adrenal Hyperplasia and Cushing's Syndrome. He is "impressed" with the early efficacy data for livoletide and nevanimibe, which show "reasonably clean" safety and tolerability, and sees Millendo as a leader in orphan endocrine diseases, Olson tells investors.
BOLD Audentes Therapeutics
$29.60

-0.35 (-1.17%)

04/26/19
HCWC
04/26/19
NO CHANGE
Target $48
HCWC
Buy
Audentes Therapeutics price target raised to $48 from $44 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay raised his price target for Audentes Therapeutics to $48 from $44 saying the company is delivering on its pipeline expansion. He keeps a Buy rating on the shares.
05/01/19
PIPR
05/01/19
NO CHANGE
Target $55
PIPR
Overweight
Piper Jaffray bullish on Audentes Therapeutics after AT132 update
Piper Jaffray analyst Christopher Raymond reiterates an Overweight rating and a $32 price target on Audentes Therapeutics following a "positive" update for AT132 at ASGCT. Clinical benefit continues to be demonstrated in all patients in Cohort 1 with additional improvements across measures with now four patients ventilator independent and further improvement in muscle biopsies observed, he notes, adding that patients in Cohort 2 demonstrated accelerated pathological recovery in muscle biopsy samples at 24 weeks, with additional benefits highlighted in neuromuscular function and reductions in ventilator dependence.
04/17/19
LEER
04/17/19
NO CHANGE
Target $48
LEER
Outperform
Audentes Therapeutics price target raised to $48 from $37 at SVB Leerink
SVB Leerink analyst Joseph Schwartz raised his price target for Audentes Therapeutics to $48 from $37, while reiterating an Outperform rating on the shares. The analyst notes that the company has expanded its pipeline to include Pompe disease and more recently, Duchenne muscular dystrophy and myotonic dystrophy.
04/26/19
SBSH
04/26/19
DOWNGRADE
SBSH
Sell
Audentes Therapeutics downgraded to Sell from Neutral at Citi
CALA Calithera Biosciences
$3.78

-0.135 (-3.45%)

05/30/19
SBSH
05/30/19
INITIATION
Target $10
SBSH
Buy
Calithera Biosciences assumed with a Buy at Citi
Citi analyst Mohit Bansal assumed coverage Calithera Biosciences with a Buy rating and $10 price target. Under a prior analyst, Citi had a Buy rating on the shares with a $7 price target. Positive data mid-year from the small metastatic renal cell carcinoma trial could have read-through to the Cabo trial, Bansal tells investors in a research note.
DERM Dermira
$7.63

-0.19 (-2.43%)

04/18/19
CANT
04/18/19
NO CHANGE
Target $25
CANT
Overweight
Cantor sees 'golden egg' potential in Dermira, boosts price target to $25
Cantor Fitzgerald analyst Louise Chen raised her price target for Dermira to $25 from $20 and reiterates an Overweight rating on the shares. The stock in afternoon trading is up 14c to $11.27. Peak sales potential of Qbrexza for hyperhidrosis and lebrikizumab for atopic dermatitis are underappreciated, Chen tells investors in a research note ahead of the long Easter weekend titled "We Think This Bunny Could Lay The Golden Egg." The analyst also thinks Dermira is an "interesting company in a consolidating space." Her new price target reflects the inclusion of Lebrikizumab sales following the positive Phase 2b data readout earlier this year.
04/18/19
CANT
04/18/19
NO CHANGE
Target $25
CANT
Overweight
Dermira price target raised to $25 from $20 at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen raised her price target on Dermira to $25 as she is now including an estimate for sales for lebrikizumab following the positive Phase 2b data readout in atopic dermatitis. Chen keeps an Overweight rating on Dermira shares.
03/27/19
HCWC
03/27/19
NO CHANGE
Target $22
HCWC
Buy
Dermira price target raised to $22 from $13 at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao raised his price target for Dermira to $22 from $13 saying the company last week announced "very strong" data from the Phase 2B Treble study for lebrikizumab in the treatment of atopic dermatitis. The data arguably represents a "best case" scenario for Dermira, Tsao tells investors in a research note. The results were "sufficiently compelling to put to rest any debate" whether the company should move into lebrikizumab into Phase 3 testing, contends the analyst. He raised his peak sales estimate for lebrikizumab to $2.5B, up from $1.5B, and keeps a Buy rating on Dermira.
06/06/19
MZHO
06/06/19
UPGRADE
Target $14
MZHO
Buy
Dermira upgraded to Buy from Neutral at Mizuho
Mizuho analyst Irina Koffler upgraded Dermira to Buy from Neutral while lowering her price target for the shares to $14 from $17. The analyst expects Almirall to exercise its European rights to lebrikizumab and she sees potential upside from other strategic alternatives. She attributes the 40% share selloff since April to financing uncertainty and the "lackluster" performance of Qbrexza. However, she views Dermira's risk/reward as favorable into Almirall's decision. The stock trades in-line with Koffler's $9 bear-case scenario, which assumes that Almirall opts out of the deal.
EDIT Editas Medicine
$23.17

-0.71 (-2.97%)

02/07/19
BTIG
02/07/19
INITIATION
BTIG
Buy
Editas Medicine initiated with a Buy at BTIG
BTIG analyst Amanda Murphy initiated Editas Medicine with a Buy rating and $30 price target. Murphy sees Editas having the broadest CRISPR toolbox, noting that "with its IP portfolio, Editas can target ten times as many sites in the genome relative to wild-type spCas9 and roughly 95% of the human genome in total."
04/11/19
EVER
04/11/19
INITIATION
Target $34
EVER
Outperform
Editas Medicine initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ravi Mehrotra initiated Editas Medicine (EDIT) with an Outperform rating and a price targets of $34. The analyst cites the company's "strong clinical positioning of lead program EDIT-101", saying that if its efficacy is demonstrated in LCA-10 and proven durable, it will likely have "significant uptake over Sepofarsen, which requires chronic dosing." Mehrotra adds that Editas Medicine's partnership with Allergan (AGN) "adds reinforcement".
04/22/19
BTIG
04/22/19
NO CHANGE
BTIG
Buy
BTIG raises price targets on Editas Medicine, CRISPR Therapeutics
BTIG analyst Amanda Murphy raised her price target on Buy-rated Editas Medicine (EDIT) to $33 from $30 and CRISPR Therapeutics (CRSP) to $49 from $43 as part of her first installment of a broader research note analyzing hiring trends in the gene therapy space. The analyst notes that the latter is "aggressively adding process development/CMC/Tech capabilities in cell therapy, including late stage process development resources", which may suggest that the company is "farther along" in the development of CTX110. Murphy also observes that Editas Medicine appears to be "shifting focus to engineered stem cell therapy while still investing in allo CAR-T and potentially new in vivo indications and delivery vectors."
10/09/18
GUGG
10/09/18
INITIATION
GUGG
Neutral
Editas Medicine initiated with a Neutral at Guggenheim
Guggenheim analyst Whitney Ijem initiated Editas Medicine with a Neutral rating, calling the company's potential "mostly theoretical at this point as the company has yet to identify programs where these assets can be uniquely deployed."
PIRS Pieris Pharmaceuticals
$4.99

0.15 (3.10%)

05/14/19
BARD
05/14/19
INITIATION
Target $5
BARD
Outperform
Pieris Pharmaceuticals initiated with an Outperform at Baird
Baird analyst Madhu Kumar initiated Pieris Pharmaceuticals with an Outperform rating and $5 price target, saying he believe's Pieris' anticalin platform has the potential to disrupt biologic therapies in the respiratory and oncology spaces. The analyst called out the company's Phase 1 single ascending dose results for anti-interleukin-4 receptor a Ac PRS060 as potentially validating the drug's utility in asthma and serve as a positive catalyst for shares.
05/13/19
BARD
05/13/19
INITIATION
Target $5
BARD
Outperform
Pieris Pharmaceuticals initiated with an Outperform at Baird
Baird analyst Madhu Kumar initiated Pieris Pharmaceuticals with an Outperform and $5 price target.
07/29/19
WBLR
07/29/19
NO CHANGE
WBLR
Outperform
Updates 'very positive' for upcoming Pieris presentation, says William Blair
Pieris Pharmaceuticals (PIRS) will present Phase Ib safety and efficacy results with PRS-060, an inhaled IL-4R alpha inhibitor, at the upcoming European Respiratory Society International Congress, held September 28 through October 2, William Blair analyst Matt Phipps tells investors in a research note. The poster presentation to be presented on October 1 is titled, "Multiple ascending dose study of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma," the analyst point out. In addition, AstraZeneca (AZN) plans to initiate a Phase II trial with AZD1402/PRS-060 in the second half of this year, according to its recent earnings presentation, adds Phipps. He views these updates as "very positive" for the upcoming presentation, and believes PRS-060 has "significant potential" in the treatment of asthma patients. Phipps keeps an Outperform rating on Pieris Pharmaceuticals.
07/30/19
BARD
07/30/19
DOWNGRADE
Target $5
BARD
Neutral
Pieris Pharmaceuticals downgraded to Neutral from Outperform at Baird
Baird analyst Madhu Kumar downgraded Pieris Pharmaceuticals to Neutral from Outperform with an unchanged price target of $5.

TODAY'S FREE FLY STORIES

UPS

UPS

$120.71

1.61 (1.35%)

21:22
09/20/19
09/20
21:22
09/20/19
21:22
Conference/Events
UPS management to meet with UBS »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

DIS

Disney

$132.18

-1.14 (-0.86%)

, T

AT&T

$37.92

0.78 (2.10%)

18:17
09/20/19
09/20
18:17
09/20/19
18:17
Periodicals
Disney reaches TV carriage agreement with AT&T, Bloomberg says »

The deal includes ESPN on…

DIS

Disney

$132.18

-1.14 (-0.86%)

T

AT&T

$37.92

0.78 (2.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

BA

Boeing

$379.33

-5.28 (-1.37%)

18:15
09/20/19
09/20
18:15
09/20/19
18:15
Periodicals
Icelandair reaches deal for Boeing to cover costs associated with 737, WSJ says »

Icelandair Group said it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

MCF

Contango Oil & Gas

$1.71

-0.07 (-3.93%)

17:58
09/20/19
09/20
17:58
09/20/19
17:58
Hot Stocks
Karlin Asset Management reports 11.4% passive stake in Contango Oil & Gas »

Karlin Asset Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Shares

$142.97

1.68 (1.19%)

17:41
09/20/19
09/20
17:41
09/20/19
17:41
Hot Stocks
SPDR Gold Shares holdings rise to 894.15MT from 883.60MT »

This is the highest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VXRT

Vaxart

$0.58

-0.0307 (-5.03%)

17:37
09/20/19
09/20
17:37
09/20/19
17:37
Syndicate
Vaxart files to sell 15.6M shares of common stock »

H.C. Wainwright acted as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$217.69

-3.22 (-1.46%)

17:34
09/20/19
09/20
17:34
09/20/19
17:34
Periodicals
Apple given tariff exclusion on certain Mac Pro parts, Bloomberg says »

Apple has received U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IIVI

II-VI

$39.05

-0.5 (-1.26%)

, CPE

Callon Petroleum

$4.53

-0.015 (-0.33%)

17:31
09/20/19
09/20
17:31
09/20/19
17:31
Hot Stocks
II-VI to enter S&P 400; Callon Petroleum, PriceSmart to enter S&P SmallCap600 »

S&P SmallCap 600…

IIVI

II-VI

$39.05

-0.5 (-1.26%)

CPE

Callon Petroleum

$4.53

-0.015 (-0.33%)

PSMT

PriceSmart

$60.29

-0.39 (-0.64%)

FNSR

Finisar

$24.31

1.25 (5.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 02

    Oct

  • 30

    Oct

NVR

NVR

$3,632.55

-30.45 (-0.83%)

, JEF

Jefferies Financial Group

$19.47

-0.19 (-0.97%)

17:26
09/20/19
09/20
17:26
09/20/19
17:26
Hot Stocks
NVR to replace Jefferies Financial Group in the S&P 500 at open on September 26 »

NVR (NVR) will replace…

NVR

NVR

$3,632.55

-30.45 (-0.83%)

JEF

Jefferies Financial Group

$19.47

-0.19 (-0.97%)

SPB

Spectrum Brands

$49.66

-1.395 (-2.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

NOC

Northrop Grumman

$368.25

-7.45 (-1.98%)

17:24
09/20/19
09/20
17:24
09/20/19
17:24
Hot Stocks
Northrop Grumman subsidiary awarded $1.12B Missile Defense Agency contract »

Orbital Sciences, or OSC,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSMT

PriceSmart

$60.29

-0.39 (-0.64%)

, FNSR

Finisar

$24.31

1.25 (5.42%)

17:23
09/20/19
09/20
17:23
09/20/19
17:23
Hot Stocks
Breaking Hot Stocks news story on PriceSmart, Finisar »

PriceSmart to replace…

PSMT

PriceSmart

$60.29

-0.39 (-0.64%)

FNSR

Finisar

$24.31

1.25 (5.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

IIVI

II-VI

$39.05

-0.5 (-1.26%)

, CPE

Callon Petroleum

$4.53

-0.015 (-0.33%)

17:22
09/20/19
09/20
17:22
09/20/19
17:22
Hot Stocks
Breaking Hot Stocks news story on II-VI, Callon Petroleum »

II-VI to replace Callon…

IIVI

II-VI

$39.05

-0.5 (-1.26%)

CPE

Callon Petroleum

$4.53

-0.015 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 02

    Oct

NVR

NVR

$3,632.55

-30.45 (-0.83%)

17:20
09/20/19
09/20
17:20
09/20/19
17:20
Hot Stocks
Breaking Hot Stocks news story on NVR »

NVR to replace Jefferies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NHYDY

Norsk Hydro

$0.00

(0.00%)

17:12
09/20/19
09/20
17:12
09/20/19
17:12
Hot Stocks
Norsk Hydro discloses federal court in Brazil lifts embargo on Alunortes »

The Federal Court in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RESN

Resonant

$3.05

0.02 (0.66%)

17:03
09/20/19
09/20
17:03
09/20/19
17:03
Conference/Events
Resonant participates in a conference call with Loop Capital »

Semiconductor Analysts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 12

    Nov

NINE

Nine Energy Services

$6.73

-0.33 (-4.67%)

17:02
09/20/19
09/20
17:02
09/20/19
17:02
Syndicate
Breaking Syndicate news story on Nine Energy Services »

Nine Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATOM

Atomera

$3.70

0.17 (4.82%)

17:00
09/20/19
09/20
17:00
09/20/19
17:00
Conference/Events
Atomera participates in a conference call with Loop Capital »

Semiconductor Analysts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPWR

Monolithic Power

$154.21

-2 (-1.28%)

16:50
09/20/19
09/20
16:50
09/20/19
16:50
Conference/Events
Monolithic Power participates in a conference call with Loop Capital »

Semiconductor Analysts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

AAPL

Apple

$217.69

-3.22 (-1.46%)

16:45
09/20/19
09/20
16:45
09/20/19
16:45
Periodicals
Breaking Periodicals news story on Apple »

Apple given tariff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDA

IDACORP

$111.26

0.93 (0.84%)

16:36
09/20/19
09/20
16:36
09/20/19
16:36
Hot Stocks
IDACORP raises quarterly dividend to 67c from 63c per share »

The company states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Nov

MO

Altria Group

$40.80

0.69 (1.72%)

16:33
09/20/19
09/20
16:33
09/20/19
16:33
Hot Stocks
Altria Group recommends rejection of amended mini-tender by TRC »

Altria Group states it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$0.00

(0.00%)

, AL

Air Lease

$42.68

-0.615 (-1.42%)

16:32
09/20/19
09/20
16:32
09/20/19
16:32
Hot Stocks
Air Lease announces delivery of new A321-200neo to Air Astana »

Air Lease Corporation…

EADSY

Airbus

$0.00

(0.00%)

AL

Air Lease

$42.68

-0.615 (-1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

16:30
09/20/19
09/20
16:30
09/20/19
16:30
Options
Preliminary option volume of 23.5M today »

Preliminary option volume…

PSX

Phillips 66

$103.26

0.14 (0.14%)

16:28
09/20/19
09/20
16:28
09/20/19
16:28
Periodicals
Phillips 66 says Beaumont oil terminal ops still shut down, Reuters says »

Phillips 66 said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

POST

Post Holdings

$105.73

0.335 (0.32%)

16:24
09/20/19
09/20
16:24
09/20/19
16:24
Hot Stocks
Post files IPO for active nutrition unit BellRing Brands »

Post Holdings, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.